CN110951884A - New application of LINC02166 in diagnosis and treatment of gastric cancer - Google Patents
New application of LINC02166 in diagnosis and treatment of gastric cancer Download PDFInfo
- Publication number
- CN110951884A CN110951884A CN201911401338.7A CN201911401338A CN110951884A CN 110951884 A CN110951884 A CN 110951884A CN 201911401338 A CN201911401338 A CN 201911401338A CN 110951884 A CN110951884 A CN 110951884A
- Authority
- CN
- China
- Prior art keywords
- gastric cancer
- linc02166
- coding rna
- treatment
- long
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Analytical Chemistry (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
Abstract
The invention relates to a new application of LINC02166 in diagnosis and treatment of gastric cancer, in particular to an application of LINC02166 as a gastric cancer diagnosis marker in preparation of a gastric cancer diagnosis reagent and an application of LINC02166 as a treatment target in preparation of a gastric cancer treatment drug. The invention proves that LINC02166 can be used as a diagnosis marker and a treatment target of gastric cancer, the gastric cancer can be diagnosed early by detecting the expression level of LINC02166, and the LINC02166 is used as a medicine target to assist clinical operation treatment to improve the cure rate of gastric cancer patients and improve the life quality of the patients by inhibiting the expression of LINC 02166.
Description
Technical Field
The invention belongs to the field of biomedicine, and relates to a new application of LINC02166 in diagnosis and treatment of gastric cancer.
Background
Gastric Cancer (GC) is the second largest cancer worldwide leading to death. The rapid progression and metastasis of the disease results in a poor prognosis. In order to improve early diagnosis and targeted therapy of GC, understanding of its underlying molecular mechanisms and identifying new, effective biomarkers and therapeutic targets are urgently needed.
Long-chain non-coding RNAs (lncrnas) are RNA molecules with transcripts longer than 200nt, different from other small-molecule non-coding RNAs, which can regulate RNA metabolism, protein functional activity, histone modification and chromatin remodeling in a cis (in cis) or trans (in trans) action manner, and are widely involved in cellular biological processes at epigenetics, transcription and post-transcriptional levels. Non-coding RNA (ncrna) is RNA that cannot be translated into protein. Two main categories are distinguished: small RNAs (< 200NT) and lncRNAs. Small ncRNA, including small RNA, siRNA and DNA, has been demonstrated to play an important role in gastric carcinogenesis. In recent years, a number of studies have shown that lncRNAs are involved in the development of a variety of diseases, having a variety of functions in a wide range of biological processes, particularly in connection with the development of human cancer. The study showed that: in addition to these coding genes, which have been extensively studied, abnormal expression of long noncoding RNAs (lncRNAs) is also involved in tumor malignant progression. More and more researches prove that the lncRNAs not only play an important role in maintaining the normal physiological functions and the development process of the body, but also have close relation between the abnormal expression and the occurrence and the development of diseases, particularly the malignant development of tumors. One well-known pathogenesis of tumor involvement of oncogenic lncRNA is HOTAIR (HOX transcriptional antisense RNA), which is consistently up-regulated and is identified as a prognostic marker of patient outcome, e.g., affecting survival in a variety of human tumor patients.
Recently, many studies have shown that lncRNA is highly expressed in gastric cancer tissues. Therefore, there is an urgent need to find new lncRNAs and investigate their biological effects on gastric cancer in order to obtain potential therapeutic targets for diagnosis and gene therapy of gastric cancer.
Disclosure of Invention
The invention aims to provide a long-chain non-coding RNA marker for diagnosing and treating gastric cancer. Experiments prove that the expression level of LINC02166 in gastric cancer tissues is obviously higher than that in para-cancer tissues, so that LINC02166 can be used as a molecular marker for diagnosing and treating gastric cancer.
In order to test the purpose, the invention adopts the following technical scheme:
the invention provides an application of a reagent for detecting long-chain non-coding RNA expression in preparation of gastric cancer diagnosis products.
The long-chain non-coding RNA is named LINC02166 in NCBI, and the gene ID: 105371416, the transcript sequence of LINC02166 includes the following: genbank accession number XR-001752310.1 (having a length of 798bp, corresponding DNA sequence shown in SEQ ID NO. 1); genbank accession number XR-001752312.1 (421 bp in length, corresponding DNA sequence shown in SEQ ID NO. 2); genbank accession number XR-001752311.1 (having a length of 795bp, the corresponding DNA sequence is shown in SEQ ID NO. 3).
Further, the reagent comprises a PCR amplification primer used for detecting the LINC02166 expression level by using SYBR Green, a TaqMan probe, a molecular beacon, a double-hybridization probe or a composite probe.
In a specific embodiment of the invention, the primer sequences are shown as SEQ ID NO.4 and SEQ ID NO. 5.
The invention provides a product for gastric cancer diagnosis, which comprises an agent for detecting the expression level of LINC 02166.
Further, the reagent comprises a PCR amplification primer used for detecting the LINC02166 expression quantity by SYBR Green, a TaqMan probe, a molecular beacon, a double-hybridization probe or a composite probe.
In a specific embodiment of the invention, the primer sequences are shown as SEQ ID NO.4 and SEQ ID NO. 5.
Further, the aforementioned products include, but are not limited to, chips, kits, test strips, or high throughput sequencing platforms; the high-throughput sequencing platform is a special tool for diagnosing gastric cancer, and with the development of a high-throughput sequencing technology, the construction of an RNA expression profile of a person becomes very convenient work. By comparing the RNA expression profiles of patients with disease and normal populations, it is easy to identify which RNA abnormalities are associated with disease. Therefore, the knowledge that the abnormality of non-LINC 02166 is associated with gastric cancer in high-throughput sequencing is also within the use of LINC02166 and is also within the scope of the present invention.
The kit comprises a reagent for detecting the expression quantity of LINC02166, the reagent comprises nucleic acid combined with LINC02166 or a DNA sequence thereof, and the nucleic acid comprises SYBR Green, a TaqMan probe, a molecular beacon, a double-hybridization probe or a PCR amplification primer used when a composite probe is used for detecting the expression quantity of LINC 02166.
The chip comprises a reagent for detecting the expression level of LINC02166, wherein the reagent comprises a nucleic acid combined with LINC02166 or a DNA sequence thereof, and the nucleic acid comprises a probe capable of detecting the expression level of LINC 02166.
The test paper comprises a reagent for detecting the expression level of LINC02166, the reagent comprises nucleic acid combined with LINC02166 or a DNA sequence thereof, and the nucleic acid comprises a probe capable of detecting the expression level of LINC 02166.
The present invention provides a pharmaceutical composition for treating gastric cancer, comprising an agent that inhibits LINC 02166.
Further, the agent is not limited as long as it can inhibit the expression level of LINC02166 or inhibit the functional activity of LINC 02166.
The reagent comprises siRNA or shRNA of LINC 02166. In a specific embodiment of the invention, the siRNA sequence of LINC02166 is shown in SEQ ID NO.8 and SEQ ID NO. 9.
The pharmaceutical composition of the present invention may be administered alone or together with other drugs as a medicine. The other drug that can be administered together with the pharmaceutical composition of the present invention is not limited as long as it does not impair the effect of the therapeutic or prophylactic pharmaceutical composition of the present invention.
The pharmaceutical composition of the invention can be prepared into various dosage forms according to requirements. Including, but not limited to, tablets, solutions, granules, patches, ointments, capsules, aerosols or suppositories for transdermal, mucosal, nasal, buccal, sublingual or oral use.
The route of administration of the pharmaceutical composition of the present invention is not limited as long as it can exert the desired therapeutic or prophylactic effect, and includes, but is not limited to, intravenous, intraperitoneal, intraocular, intraarterial, intrapulmonary, oral, intravesicular, intramuscular, intratracheal, subcutaneous, transdermal, transpleural, topical, inhalation, transmucosal, cutaneous, gastrointestinal, intraarticular, intraventricular, rectal, vaginal, intracranial, intraurethral, intrahepatic. In some cases, the administration may be systemic. In some cases topical administration.
The dosage of the pharmaceutical composition of the present invention is not limited as long as the desired therapeutic effect or prophylactic effect is obtained, and can be appropriately determined depending on the symptoms, sex, age, and the like. The dose of the therapeutic or prophylactic pharmaceutical composition of the present invention can be determined using, for example, the therapeutic effect or prophylactic effect on a disease as an index.
The invention also provides the application of the long-chain non-coding RNA in preparing a medicament for treating gastric cancer.
The invention also provides the application of the reagent for inhibiting the long-chain non-coding RNA in preparing the medicine for treating gastric cancer.
Further, the reagent is as defined above.
The present invention also provides a method for diagnosing gastric cancer, comprising the steps of:
(1) obtaining a sample from a subject;
(2) detecting the expression level of LINC02166 in the subject sample;
(3) correlating the measured expression level of LINC02166 with the presence or absence of disease in the subject.
(4) If the expression level of LINC02166 is increased compared to the control, the subject is judged to have gastric cancer, or the subject is at high risk of having gastric cancer, or a gastric cancer patient is judged to have poor prognosis.
The present invention also provides a method for treating gastric cancer, comprising reducing the expression level of LINC02166 or inhibiting the functional activity of LINC 02166.
The present invention also provides a method for screening a gastric cancer drug, which can determine the effect of a tumor drug on improving tumor prognosis by measuring the expression level of LINC02166 after a test drug is added to gastric cancer cells or at a certain period after a test drug is administered to a gastric cancer model animal. More specifically, when the expression level of LINC02166 is reduced or returns to a normal level after addition or administration of a test drug, the drug can be selected as a therapeutic agent for improving the prognosis of a tumor.
In the context of the present invention, "diagnosing gastric cancer" includes determining whether a subject has gastric cancer, determining whether a subject is at risk of having gastric cancer, determining responsiveness of a gastric cancer patient to drug treatment, or determining a prognosis for a gastric cancer patient.
As used herein, "treatment" encompasses treatment-related diseases or disease states in a mammal, such as a human, having the associated disease or disorder, and includes:
(1) preventing the occurrence of a disease or condition in a mammal, particularly when the mammal is susceptible to said disease condition but has not been diagnosed as having such a disease condition;
(2) inhibiting a disease or disease state, i.e., preventing its occurrence; or
(3) Alleviating the disease or condition, i.e., causing regression of the disease or condition.
The term "treatment" generally refers to the treatment of a human or animal (e.g., as applied by a veterinarian) wherein some desired therapeutic effect is achieved, e.g., inhibiting the progression of a condition (including slowing the progression, stopping the progression), ameliorating the condition, and curing the condition. Treatment as a prophylactic measure (e.g., prophylaxis) is also included. The use of a patient who has not yet developed a condition but who is at risk of developing the condition is also encompassed by the term "treatment".
The invention has the advantages and beneficial effects that:
the invention discloses a molecular marker for diagnosing gastric cancer, which can be used for judging the early stage of gastric cancer occurrence and provides the survival rate of patients.
The therapeutic agent comprising an agent inhibiting LINC02166 of the present invention can be used as a novel therapeutic agent for gastric cancer.
Drawings
FIG. 1 shows a statistical chart of the inhibition of LINC02166 expression measured by QPCR.
Detailed Description
The present invention will be described in further detail with reference to the accompanying drawings and examples. The following examples are intended to illustrate the invention only and are not intended to limit the scope of the invention. Experimental procedures without specific conditions noted in the examples, generally following conventional conditions, such as Sambrook et al, molecular cloning: the conditions described in the laboratory Manual (New York: Coldspring harbor laboratory Press,1989), or according to the manufacturer's recommendations.
Example 1 study of differential expression of LncRNA
1. Study object
Surgical specimens (gastric cancer tissues and corresponding paracancerous normal tissues) of 50 primary gastric cancer patients subjected to gastric carcinoma radical surgery in tumor surgery in hospitals were collected. 30 men and 20 women in 50 patients; the patients are 38-79 years old, and the average age is 61 years old, and the patients have not received adjuvant treatment before operation. Immediately storing the tissue specimen at-80 ℃ after RNA extraction.
Grouping standard: a. primary gastric cancer is diagnosed before operation, and the cancer is not treated; b. no other malignancies were merged; c. no other complications such as gastric perforation, gastrointestinal hemorrhage, gastrointestinal obstruction and the like exist, and the general condition of the patient before the operation is good; d. no other chronic diseases, such as hypertension, diabetes, etc.
2. Detection at the transcriptional level
Total RNA was extracted from each of the experimental group (gastric cancer tissue) and the control group (adjacent normal stomach tissue) using RNAassoplus (TaKaRa, Shiga, Japan), and the concentration and purity of the RNA were measured using a spectrophotometer. It was reverse-transcribed into complementary DNA (cDNA) using PrimeScript reverse transcriptase (TaKaRa, Shiga, Japan). cDNA as template, according to SYBRGREEN EX TaqTMThe reaction system and reaction times required by the specifications (TaKaRa, Shiga, Japan) were QPCR performed on LightCycler480, all the results were repeated 3 times, and the results were calculated at 2- △△ CT and statistically analyzed.GAPDH was used as the reference gene for the experiments.LINC 02166 upstream primer: 5'-TACCTTTGGAACACCCTA-3' (SEQ ID NO.4), downstream primer: 5'-ACAGAGACAAGTGAATGG-3' (SEQ ID NO.5), GAPDH upstream primer: 5'-TCATGGGTGTGAACCATGAGAA-3' (SEQ ID NO.6), and downstream primer: 5'-GGCATGGACTGTGGTCATGAG-3' (SEQ ID NO. 7).
3. Results
The statistical results are shown in fig. 1, the expression level of LINC02166 in the gastric cancer tissue is obviously increased, about 9.6 times, compared with the tissue beside the cancer, and the difference has statistical significance (P < 0.05). Using the GEO database for electronic validation, ROC curve analysis showed that LINC02166 has an AUC value of 0.7814 in differentiating between gastric cancer patients and normals.
Example 2 inhibition of LINC02166 expression
1. Cell culture and transfection
Cell culture: the gastric cancer cell line BGC-823 is prepared from DMEM containing 10% FBS and placed in 5% CO2And saturated humidity, and culturing in a carbon dioxide incubator at 37 ℃. The culture medium was changed every two days and the cells were passaged by digestion with 0.25% trypsin.
siRNA transfection: the day before transfection, cells are digested and plated onto a petri dish or plate in an amount that ensures a density of 30-50% at the next day of transfection. The siRNA transfection was performed strictly according to LipofectaminTM2000, the culture was continued for 48h after 4-6h by replacing fresh culture medium containing 10% FBS.
2. SiRNA design
Design of siRNA (small interfering RNA): by BLAST search, siRNA sequences were designed in the specific sequence region of LINC 02166:
siRNA-LINC02166
sense strand: 5'-AUGAUUACUGAAAUCAGUCUC-3' (SEQ ID NO. 8); antisense strand: 5'-GACUGAUUUCAGUAAUCAUCA-3' (SEQ ID NO. 9).
The above siRNA was synthesized by Shanghai Jima pharmaceutical technology, Inc., while the company provided negative control siRNA (siRNA-NC).
3. Detection of siRNA interference Using QPCR assay
The procedure is as in example 1.
4. Results
After siRNA transfects gastric cancer cell strain BGC823, change of LncRNA transcription level is detected by QPCR. The result shows that the expression level of LncRNA in the experimental group cell (siRNA-LncRNA, the relative expression amount is 35.97 +/-4.27%) is obviously reduced compared with that in the control group cell (siRNA-NC, the relative expression amount is 100%), and the difference has statistical significance (P <0.05), which indicates that the siRNA-LncRNA can obviously inhibit the expression of the intracellular LINC 02166.
Example 3 measurement of ability to inhibit LINC02166 expression to proliferate gastric cancer cell
1. The method comprises the following steps:
BGC-823 cells in logarithmic growth phase are taken and inoculated on a 96-well culture plate, after the cells are cultured for 12 hours, siRNA-LncRNA and siRNA-NC are transfected respectively, and after 4-6 hours, DMEM containing 10% FBS is replaced to continue culturing for 72 hours; and adding 10 mu LCCK8 to each well of each plate, incubating for 2h in an incubator, and detecting the absorbance value with the wavelength of 450nm by using a microplate reader. The experiment was repeated 3 times and cell growth curves were plotted.
2. Statistical analysis
The experimental data are expressed as mean-squared-off standard deviations (MS-SD) using SPSS15.0 statistical software, and subjected to one-way analysis of variance (ANOVA) or t-test. P <0.05 is statistically significant for the differences.
3. Results
The results showed that 72h after transfection, the cell growth rate of siRNA-LncRNA group (1.119 + -0.032) was significantly decreased (P <0.05) compared to siRNA-NC (1.546 + -0.052). The result shows that the inhibition of LINC02166 expression has an inhibition effect on the proliferation capacity of a gastric cancer cell strain BGC 823.
The above description of the embodiments is only intended to illustrate the method of the invention and its core idea. It should be noted that, for those skilled in the art, without departing from the principle of the present invention, several improvements and modifications can be made to the present invention, and these improvements and modifications will also fall into the protection scope of the claims of the present invention.
Sequence listing
<110> Beijing, the deep biometric information technology GmbH
New application of LINC02166 in diagnosis and treatment of gastric cancer
<160>9
<170>SIPOSequenceListing 1.0
<210>1
<211>798
<212>DNA
<213> human source (Homo sapiens)
<400>1
gccttatttt agggtgaagc ccgggcagcc gacccggctg cgccgtagtg ggaggccacg 60
gcgattaccc aggtgaaggt cttccagccc agccctggaa ggtggaaaaa gaaaagttga 120
catggaatgt ttaggaagca ccattggtcc aggtccagga tcggggcagc cagcatgtcc 180
tctaatctgg cttcactgtt gaaatccagt cgagcaagca gggcccaaac cactgcgaga 240
ccagctcggt cgggcccaaa ccaccgccca ctgcgagacc agctcggtcg ggcccaaacc 300
accgcccact gcgggaccag ctcggtcggg cccaaaccac cgcccactgc gggaccagct 360
cggtcgggcc caaaccactg cccactgcgg gaccagctcg gtcgtggaga ccctaaccca 420
gcggcgctag aggaattaaa gaaacacaca cagaaatata ggtacctcgc aagggttttt 480
tgcatgtctg atacctacgg ctccaacagg acccactgac tgatgatggc tccacctgga 540
cctgccaact actcctgcag ccccacccag aagcggttca gcacacggga ggatcctgtc 600
tcacacccta cgatggcccc ccgcccccac aacccatcag cagcaagcac ccactgccaa 660
gctaccccac cccttccccc aaactacctt tggaacaccc tagtccccaa attcttgggg 720
agactgattt cagtaatcat caaattctgg tctcccattc acttgtctct gtgtgaatta 780
aaccctttct ctattgca 798
<210>2
<211>421
<212>DNA
<213> human source (Homo sapiens)
<400>2
cttattttag ggtgaagccc gggcagccga cccggctgcg ccgtagtggg aggccacggc 60
gattacccag gtgaaggtct tccagtacct cgcaagggtt ttttgcatgt ctgataccta 120
cggctccaac aggacccact gactgatgat ggctccacct ggacctgcca actactcctg 180
cagccccacc cagaagcggt tcagcacacg ggaggatcct gtctcacacc ctacgatggc 240
cccccgcccc cacaacccat cagcagcaag cacccactgc caagctaccc caccccttcc 300
cccaaactac ctttggaaca ccctagtccc caaattcttg gggagactga tttcagtaat 360
catcaaattc tggtctccca ttcacttgtc tctgtgtgaa ttaaaccctt tctctattgc 420
a 421
<210>3
<211>795
<212>DNA
<213> human source (Homo sapiens)
<400>3
gggcagccga cccggctgcg ccgtagtggg aggccacggc gattacccag gtgaaggtct 60
tccaggtgag acgggttccc ccagcccagc cctggaaggt ggaaaaagaa aagttgacat 120
ggaatgttta ggaagcacca ttggtccagg tccaggatcg gggcagccag catgtcctct 180
aatctggctt cactgttgaa atccagtcga gcaagcaggg cccaaaccac tgcgagacca 240
gctcggtcgg gcccaaacca ccgcccactg cgagaccagc tcggtcgggc ccaaaccacc 300
gcccactgcg ggaccagctc ggtcgggccc aaaccaccgc ccactgcggg accagctcgg 360
tcgggcccaa accactgccc actgcgggac cagctcggtc gtggagaccc taacccagcg 420
gcgctagagg aattaaagaa acacacacag aaatataggt acctcgcaag ggttttttgc 480
atgtctgata cctacggctc caacaggacc cactgactga tgatggctcc acctggacct 540
gccaactact cctgcagccc cacccagaag cggttcagca cacgggagga tcctgtctca 600
caccctacga tggccccccg cccccacaac ccatcagcag caagcaccca ctgccaagct 660
accccacccc ttcccccaaa ctacctttgg aacaccctag tccccaaatt cttggggaga 720
ctgatttcag taatcatcaa attctggtct cccattcact tgtctctgtg tgaattaaac 780
cctttctcta ttgca 795
<210>4
<211>18
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>4
tacctttgga acacccta 18
<210>5
<211>18
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>5
acagagacaa gtgaatgg 18
<210>6
<211>22
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>6
tcatgggtgt gaaccatgag aa 22
<210>7
<211>21
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>7
ggcatggact gtggtcatga g 21
<210>8
<211>21
<212>RNA
<213> Artificial Sequence (Artificial Sequence)
<400>8
augauuacug aaaucagucu c 21
<210>9
<211>21
<212>RNA
<213> Artificial Sequence (Artificial Sequence)
<400>9
gacugauuuc aguaaucauc a 21
Claims (10)
1. The application of the reagent for detecting the expression of the long-chain non-coding RNA in the preparation of gastric cancer diagnosis products; the long non-coding RNA is LINC 02166.
2. The use of claim 1, wherein the reagent comprises PCR amplification primers used for detecting the expression level of the long non-coding RNA by using SYBR Green, TaqMan probes, molecular beacons, two-hybrid probes, or composite probes.
3. The use according to claim 2, wherein the primer sequences are shown as SEQ ID No.4 and SEQ ID No. 5.
4. The use according to any one of claims 1 to 3, wherein the product comprises a kit, chip, or strip.
5. A product for gastric cancer diagnosis comprising an agent for detecting the expression of the long non-coding RNA of any one of claims 1 to 4.
6. The product of claim 5, wherein the reagent comprises SYBR Green, TaqMan probes, molecular beacons, two-hybrid probes, or PCR amplification primers used in the detection of the expression level of the long non-coding RNA.
7. The product of claim 6, wherein the primer sequences are shown as SEQ ID No.4 and SEQ ID No. 5.
8. A pharmaceutical composition for treating gastric cancer, comprising an agent that inhibits the long non-coding RNA of any one of claims 1-4.
9. The pharmaceutical composition of claim 8, wherein the agent comprises an agent that inhibits the level of long-chain non-coding RNA, or an agent that inhibits the functional activity of the long-chain non-coding RNA.
10. Use of the long non-coding RNA of any one of claims 1-4 in the manufacture of a medicament for the treatment of gastric cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911401338.7A CN110951884A (en) | 2019-12-31 | 2019-12-31 | New application of LINC02166 in diagnosis and treatment of gastric cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911401338.7A CN110951884A (en) | 2019-12-31 | 2019-12-31 | New application of LINC02166 in diagnosis and treatment of gastric cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110951884A true CN110951884A (en) | 2020-04-03 |
Family
ID=69985086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911401338.7A Pending CN110951884A (en) | 2019-12-31 | 2019-12-31 | New application of LINC02166 in diagnosis and treatment of gastric cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110951884A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130178428A1 (en) * | 2011-11-30 | 2013-07-11 | Dave S.B. HOON | Long noncoding rna (lncrna) as a biomarker and therapeutic marker in cancer |
| WO2016197592A1 (en) * | 2015-06-11 | 2016-12-15 | 中国人民解放军第二军医大学 | Application of long noncoding rna, hnf1a-as1, in preparing drug for treating human malignant solid tumor |
| CN106701900A (en) * | 2015-11-16 | 2017-05-24 | 上海市东方医院 | Long-chain noncoding RNA HERC2P3 gene and application thereof in gastric cancer |
| CN108559779A (en) * | 2018-06-13 | 2018-09-21 | 中国医学科学院北京协和医院 | Diagnosis and treatment marker of the long-chain non-coding RNA as gastric cancer |
| WO2019189772A1 (en) * | 2018-03-30 | 2019-10-03 | 北海道公立大学法人 札幌医科大学 | Cancer-treating agent that targets at long-chain non-coding rna, and cancer diagnosis method |
-
2019
- 2019-12-31 CN CN201911401338.7A patent/CN110951884A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130178428A1 (en) * | 2011-11-30 | 2013-07-11 | Dave S.B. HOON | Long noncoding rna (lncrna) as a biomarker and therapeutic marker in cancer |
| WO2016197592A1 (en) * | 2015-06-11 | 2016-12-15 | 中国人民解放军第二军医大学 | Application of long noncoding rna, hnf1a-as1, in preparing drug for treating human malignant solid tumor |
| CN106701900A (en) * | 2015-11-16 | 2017-05-24 | 上海市东方医院 | Long-chain noncoding RNA HERC2P3 gene and application thereof in gastric cancer |
| WO2019189772A1 (en) * | 2018-03-30 | 2019-10-03 | 北海道公立大学法人 札幌医科大学 | Cancer-treating agent that targets at long-chain non-coding rna, and cancer diagnosis method |
| CN108559779A (en) * | 2018-06-13 | 2018-09-21 | 中国医学科学院北京协和医院 | Diagnosis and treatment marker of the long-chain non-coding RNA as gastric cancer |
Non-Patent Citations (1)
| Title |
|---|
| "Gene ID: 105371416", 《GENE》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Richards et al. | A functional variant in HOXA11-AS, a novel long non-coding RNA, inhibits the oncogenic phenotype of epithelial ovarian cancer | |
| Peng et al. | Promoter hypermethylation of let-7a-3 is relevant to its down-expression in diabetic nephropathy by targeting UHRF1 | |
| Wei et al. | miR-532-5p is a prognostic marker and suppresses cells proliferation and invasion by targeting TWIST1 in epithelial ovarian cancer. | |
| US20190112665A1 (en) | Compositions and methods for prognosis of ovarian cancer | |
| CN108531596B (en) | Application of lncRNA as biomarker in diagnosis and treatment of gastric cancer | |
| CN113462780B (en) | Marker and kit for auxiliary diagnosis of prostate cancer | |
| CN108559779B (en) | Long-chain non-coding RNA as diagnosis and treatment marker of gastric cancer | |
| CN111647660B (en) | Application of Linc01559 in diagnosis and treatment of gastric cancer | |
| CN111304326B (en) | Reagent for detecting and targeting lncRNA biomarker and application of reagent in hepatocellular carcinoma | |
| Xu et al. | Mechanism of lncRNA FEZF1-AS1 in promoting the occurrence and development of oral squamous cell carcinoma through targeting miR-196a. | |
| CN112322741A (en) | Application of biomarker RP11-54A9.1 in prediction of oral squamous cell carcinoma and treatment thereof | |
| US20120108655A1 (en) | Methods of Diagnosing and Treating Carcinomas | |
| CN108251528B (en) | Application of LINC01814 in diagnosis and treatment of gastric cancer | |
| Ni et al. | MicroRNA-30c suppressed giant-cell tumor of bone cell metastasis and growth via targeting HOXA1. | |
| CN112516317B (en) | Pharmaceutical composition for preventing and treating cancer and application thereof | |
| CN106906290B (en) | CDSN as diagnosis and treatment target of tongue squamous cell carcinoma | |
| CN111518913B (en) | Non-coding RNA-LINC01819 for diagnosis and treatment of gastric cancer | |
| CN111088355A (en) | Molecular marker and kit for gastric cancer diagnosis | |
| CN110923326A (en) | Application of LINC01909 in preparation of cancer treatment drug and diagnostic kit | |
| CN110951881A (en) | Novel approach for diagnosis and treatment of gastric cancer | |
| Feng et al. | Association of the upregulation of LncRNA00673 with poor prognosis for colorectal cancer. | |
| CN110951884A (en) | New application of LINC02166 in diagnosis and treatment of gastric cancer | |
| CN110951883A (en) | Application of LINCR-0001 in preparation of gastric cancer diagnosis product and treatment medicine | |
| CN110904240A (en) | Application of LINC00884 as cancer diagnosis and treatment marker | |
| CN111733248B (en) | Application of LOC158435 as biomarker for diagnosing and treating laryngeal squamous cell carcinoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |